Previous 10 | Next 10 |
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Summary 2022 has been a terrible year for a once-promising TGTX. Maybe the FDA decision on December 28 will help us break even. I don't have any further expectations from TGTX. TG Therapeutics, Inc. ( TGTX ) is an unfortunate story for investors. Just like with A...
Amarin Corporation Plc (AMRN) H.C. Wainwright Global Investment Conference September 12, 2022, 09:00 ET Company Participants Karim Mikhail - President, CEO & Director Thomas Reilly - CFO & SVP Conference Call Participants Andrew Fein - H.C. Wainwr...
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conferenc...
Amarin Corp. ( NASDAQ: AMRN ) shares are down 21% in Monday afternoon amid heavy volume. Average daily volume is ~3.7M. As of 245p ET, ~6.6M shares had traded hands. The company has been negatively impacted by generic versions of its fish oil pill Vascepa (icosapen...
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (C...
Amarin has seen sales of its lone drug, Vascepa, plummet against generic competition. Famed activist investor Alex Denner has recently taken a sizeable stake in the company. If Denner can work his magic, investors could reap huge rewards. Absent a buyout in the near future, Am...
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q2 2022 Earnings Call Aug 03, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q2 2022 Earnings Call Transcript
2022 hasn't been a good year for cardiovascular drug maker Amarin (NASDAQ: AMRN) , and this was compounded after the company released its latest set of quarterly figures Wednesday morning. Investors reacted clearly and immediately to this by trading out of the stock; as of late afte...
Best Penny Stocks To Buy Social sentiment has become a major factor in finding the best penny stocks to buy. In the past, whatever people on Reddit, Twitter, Facebook, or even Discord were saying was taken with a grain of salt. Who pays attention to retail traders, right? The rise of ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...